What Punxsutawney Phil tells us about undervalued stocks

Original Reddit post

Author presents four undervalued large-cap ideas—Keurig Dr Pepper, Paychex, Equifax, and Abbott Laboratories—arguing the market is fixated on temporary headwinds while these companies pivot to higher-margin recurring revenue.

KDP — LONG Author argues Keurig Dr Pepper is undervalued because the market is missing refreshment beverages growing 5.8% at a 55.6% gross margin. The stated catalyst is the 2025 plan to split the coffee and soda businesses, which the author says lets the market value the two segments at their true worth and creates a multiple expansion opportunity. The author sees the stock in early innings before its growth story becomes more widely recognized.

Most are missing the fact that refreshment beverages grew 5.8% with a 55.6% gross margin. The 2025 plan to split the coffee and soda businesses creates a massive potential for the market to finally value these two very different segments at their true worth. Creating a multiple expansion opportunity for the stock.

PAYX — LONG Author argues the market is overly focused on debt from the $4.1 billion Paycor deal and overlooks Paychex's 41% operating margins and 95% recurring revenue. The causal mechanism is that the move upmarket gives Paychex a new growth lever, which the author expects to overcome temporary debt concerns while 83% client retention holds. The main stated risk is the debt taken for the Paycor deal and related temporary debt concerns.

The market is overly focused on the debt taken for the $4.1 billion Paycor deal and is overlooking the incredible 41% operating margins and 95% recurring revenue. This move upmarket gives them a new growth lever that will easily overcome temporary debt concerns while they maintain a solid 83% client retention rate.

EFX — LONG Author argues Equifax is mispriced as a pure mortgage play despite non-mortgage verification services growing 10% and a cloud move generating 2.3 times more cash flow. The catalyst cited is resuming $3 billion in buybacks and hiking dividends by 28%, which the author says signals the underlying data machine is healthier than headline numbers.

Currently traded like a pure mortgage play despite the fact that their non-mortgage verification services grew 10% and their cloud move is throwing off 2.3 times more cash flow. Resuming $3 billion in buybacks and hiking dividends by 28% says that the underlying data machine is much healthier than the headline numbers.

ABT — LONG Author argues Abbott Laboratories is severely underpriced as a tech growth story because investors still mourn the $7.7 billion drop in COVID testing revenue while ignoring 13.7% organic growth in medical devices fueled by the Libre platform. The supporting factors cited are a 0.3 debt-to-equity ratio and more than five decades of dividend raises, with the author noting dividend consistency matters. The stated headwind is the market's continued focus on the prior COVID testing revenue decline.

Investors are still mourning the $7.7 billion drop in COVID testing revenue and ignoring the 13.7% organic growth in medical devices fueled by the Libre platform. They have a tiny 0.3 debt to equity ratio and over five decades of dividend raises, the market is severely underpricing a tech growth story.